Non-cognitive psychopathological symptoms as early manifestations of dementia: diagnostics and therapy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Understanding of prodromal conditions or early clinical manifestations of dementia helps early detection of the disease and can lead to the development of effective prevention measures for dementia. Mild cognitive impairment (MCI) is considered as the earliest manifestation of dementia. Non-cognitive psychopathological symptoms (NCPS) are common in MCI and occur in 35-75% of patients. The most common symptoms of NCPS include apathy, anxiety, depression, and irritability. It has been shown that the presence of NCPS in MCI increases the risk of dementia. Studies have shown the effectiveness of Cerebrolysin in preventing cognitive deficits in patients with MCI and reducing the severity of NCPS at the stage of mild and moderate dementia in Alzheimer’s disease, as well as in complex therapy of depression (in combination with an antidepressant) in elderly people and patients with organic disorders of vascular genesis.

Full Text

Restricted Access

About the authors

Igor V. Kolykhalov

Mental Health Science Center

Email: ikolykhalov@yandex.ru
PhD, Chief Researcher

References

  1. Alzheimer's Disease International. World Alzheimer Report 2015. The Global Impact of Dementia an analysis of prevalence, incidence, cost and trends. London: Alzheimer's Disease International, 2015. www.worldalzreport2015.org
  2. Rabins P.V., Schwartz S., Black B.S., et al. Predictors of progression to severe Alzheimer's disease in an incidence sample. Alzheimers Dement. 2013;9(2):204-7.
  3. Peters M.E., Schwartz S., Han D., et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the Cache County Dementia Progression Study. Am. J. Psychiatry. 2015;172(5):460-65. doi: 10.1176/appi.ajp.2014.14040480.
  4. Steinberg M., Shao H., Zandi P., et al. Cache County Investigators. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int. J. Geriatr. Psychiatry. 2008;23(2):170-77. doi: 10.1002/gps.1858.
  5. Wadsworth L.P., Lorius N., Donovan N.J., et al. Neuropsychiatric symptoms and global functional impairment along the Alzheimer's continuum. Dement. Geriatr. Cogn. Disord. 2012;34:96-111.
  6. Rocca P., Leotta D., Liffredo C., et l. Neuropsychiatric symptoms underlying caregiver stress and insight in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2010;30:57-63.
  7. Scarmeas N., Brandt J., Albert M., et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch. Neurol. 2005;62(10):1601-8.
  8. Bachurin S.O., Gavrilova S.I., Samsonova A., et al. Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention. Pharmacol. Res. 2018;129:216-26. Doi: 10.1016/j. phrs.2017.11.021.
  9. Tuokko H., Frerichs R.J. Cognitive impairment with no dementia (CIND): longitudinal studies, the findings, and the issues. Clin. Neuropsychol. 2000;14(4):504-25.
  10. Petersen R.C. Mild cognitive impairment: transition from aging to Alzheimer's disease. In: K. Iqbal, S.S. Sisodia, B. Winblad, ed. Alzheimer's disease: advances in etiology, pathogenesis and therapeutics. John Wiley & Sons; West Sussex, England. 2001. Р. 141-51.
  11. Taragano F.E., Allegri R.F., Krupitzki H., et al. Mild behavioural impairment and risk of dementia. J. Clin. Psychiatry. 2009;70(4):584-92.
  12. Liu W., Miller B.L., Kramer J.H., et al. Behavioral disorders in the frontal and temporal variants of frontotemporal dementia. Neurology. 2004;62:742-48.
  13. Woolley J.D., Khan B.K., Murthy N.K., et al. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. J. Clin. Psychiatry 2011;72:126-33.
  14. McKhann G.M., Knopman D.S., Chertkow H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-69.
  15. Taragano F.E., Allegri R.F., Lyketsos C. Mild behavioral impairment: A prodromal stage of dementia. Dement. Neuropsychol. 2008;2(4):256-60. doi: 10.1590/S1980-57642009DN20400004.
  16. Apostolova L.G., Cummings J.L. Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dement. Geriatr. Cogn. Disord 2008;25:11-26.
  17. Rosenberg P.B., Mielke M.M., Appleby B.S., et al. The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am. J. Geriatr. Psychiatry. 2013;21:685-95.
  18. Geda Y.E., Roberts R.O., Mielke M.M., et al. Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: A population-based study. Am. J. Psychiatry. 2014;171:572-81.
  19. Kantarci K., Weigand S.D., Przybelski S.A., et al. MRI and MRS predictors of mild cognitive impairment in a population-based sample. Neurology. 2013;81:126-33.
  20. Ismail Z., Smith E.E., Geda Y., et al.; ISTAART Neuropsychiatric Symptoms Professional Interest Area. Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement. 2016;12(2):195-202. doi: 10.1016/j.jalz.2015.05.017.
  21. Beaudreau S.A., O’Hara R. Late-life anxiety and cognitive impairment: a review. Am. J. Geriatr. Psychiatry. 2008;16:790-803. Doi: 10.1097/ JGP0b013e31817945c3.
  22. Palmer K., Berger A.K., Monastero R., et al. Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology. 2007;68:1596-602.
  23. Sinoff G., Werner P. Anxiety disorder and accompanying subjective memory loss in the elderly as a predictor of future cognitive decline. Int. J. Geriatr. Psychiatry. 2003;18:951-59. doi: 10.1002/gps.1004.
  24. Pietrzak R.H., Maruff P., Woodward M., et al. Mild worry symptoms predict decline in learning and memory in healthy older adults: A 2-year prospective cohort study. Am. J. Geriatr. Psychiatry. 2012;20:266-75.
  25. Modrego P.J., Ferrandez J., Geda Y.E., et al. Depression, apolipoprotein E. genotype, and the incidence of mild cognitive impairment: a prospective cohort study. Arch. Neurol. 2006;63(3):435-40.
  26. Cooper C., Sommerlad A., Lyketsos C.G., Livingston G. Modifiable predictors of dementia in mild cognitive impairment: a systematic review and metaanalysis. Am. J. Psychiatry. 2015;172:323-34.
  27. Modrego P.J., Ferrandez J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Arch. Neurol. 2004;61(8):1290-93.
  28. Geda Y.E., Knopman D.S., Mrazek D.A., et al. Depression, apolipoprotein E. genotype, and the incidence of mild cognitive impairment: a prospective cohort study. Arch. Neurol. 2006;63(3):435-40.
  29. Panza F., Capurso C., D'Introno A., et al. Impact of depressive symptoms on the rate of progression to dementia in patients affected by mild cognitive impairment. The Italian Longitudinal Study on Aging. Int. J. Geriatr. Psychiat. 2008;23:726-34.
  30. Panza F., Frisardi V., Capurso C., et al. Late-life depression, mild cognitive impairment, and dementia: possible continuum? Am. J. Geriatr. Psychiat. 2010;18(2):98-116. Doi: 10.1097/ JGP0b013e3181b0fa13.
  31. Monastero R., Palmer K., Qiu C., et al. Heterogeneity in risk factors for cognitive impairment, no dementia: population-based longitudinal study from the Kungsholmen Project. Am. J. Geriatr. Psychiat. 2007;15:60-9.
  32. Palmer K., Di Iulio F., Varsi A.E., et al. Neuropsychiatric predictors of progression from amnestic-mild cognitive impairment to Alzheimer's disease: the role of depression and apathy. J. Alzh. Dis. 2010;20:175-83. doi: 10.3233/JAD-2010-1352.
  33. Wadsworth L.P., Lorius N., Donovan N.J., et al. Neuropsychiatric symptoms and global functional impairment along the Alzheimer's continuum. Dement.Geriatr. Cogn. Disord. 2012; 34:96-111.
  34. Onyike C.U., Sheppard J.M., Tschanz J.T., et al. Epidemiology of apathy in older adults: the Cache County Study. Am. J. Geriatr. Psychiatry. 2007;15:365-75.
  35. Geda Y.E., Smith G.E., Knopman D.S., et al. De novo genesis of neuropsychiatric symptoms in mild cognitive impairment (MCI). Int. Psychogeriatr. 2004;16:51-60.
  36. Hwang T.J., Masterman D.L., Ortiz F., et al. Mild cognitive impairment is associated with characteristic neuropsychiatrie symptoms. Alzh. Dis Assoc. Disord. 2004;18:17-21.
  37. Gauthier S., Loft H., Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int. J. Geriatr. Psychiatry 2008;23:537-45.
  38. Rodda J., Morgan S., Walker Z. Are cholinesterase inhibitors effective in the management of the behavioural and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int. Psychogeriatr. 2009;21:813-24.
  39. Гаврилова С.И. Додементные нейрокогнитивные расстройства: диагностические и терапевтические аспекты. Обозрение психиатрии и медицинской психологии. 2018;1:89-98.
  40. Гаврилова С.И., Колыхалов И.В., Федорова Я.Б. и др. Возможности превентивной терапии болезни Альцгеймера: результаты 3-летнего проспективного открытого сравнительного исследования эффективности и безопасности курсовой терапии церебролизином и кавинтоном у пожилых пациентов с синдромом мягкого когнитивного снижения. Журнал неврологии и психиатрии им. С.С. Корсакова. 2010;1:68-75.
  41. Гаврилова С.И., Колыхалов И.В., Селезнева Н.Д. и др. Влияние церебролизина на эффективность и переносимость последующей холинергической терапии у больных с болезнью Альцгеймера. Социальная и клиническая психиатрия. 1998;8(3):58-67.
  42. Селезнева Н.Д. Терапия деменции при болезни Альцгеймера. Дисс. докт. мед. наук. М., 2003.
  43. Alvarez X.A., Cacabelos R., Laredo M., et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur. J. Neurol. 2006;13(1):43-54.
  44. De Jonghe J.F., Goedhart A.W., Ooms M.E., et al. Negative symptoms in Alzheimer's disease a confirmatory factor analysis. Int. J. Geriatr. Psychiat. 2003;18:748-53.
  45. Чуканова Е.И. Сравнительный анализ эффек тивности Церебролизина при лечении пациентов с хронической ишемией мозга. Фармакоэкономические аспекты. Трудный пациент. 2011;9(1):32-7.
  46. Марута Н.А., Явдак И.А., Череднякова Е.С. Оценка нейротрофической терапии депрессии. Международный неврологический журнал. 2017;89(3):29-37.
  47. Калын Я.Б., Сафарова Т.П., Шешенин B.C., Гаврилова С.И. Сравнительная эффективность и безопасность антидепрессивной моно- и мультимодальной терапии у пожилых больных депрессией (опыт клинического применения в геронтопсихиатрическом стационаре). Журнал неврологии и психиатрии им. С.С. Корсакова. 2014;6(2):20-9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies